Keyphrases
Prospective Cohort Study
100%
Humoral Response
100%
Antifibrotic
100%
BNT162b2
100%
Idiopathic Pulmonary Fibrosis
100%
SARS-CoV-2 Vaccine
100%
Interstitial Lung Disease
100%
Anti-inflammatory Therapy
83%
Healthy Controls
66%
Antibody Titer
50%
BNT162b2 Vaccine
50%
Non-idiopathic
50%
Immunosuppression
33%
Adequate Immune Response
33%
Matched Control Group
33%
Vaccine Dose
33%
Israel
16%
High Risk
16%
Messenger RNA (mRNA)
16%
Vaccination
16%
Medical Center
16%
Two-dose
16%
Rituximab
16%
Serological Test
16%
Rabin
16%
2-dose
16%
Seropositivity Rate
16%
Anti-spike
16%
IgG Titer
16%
Observational Prospective Cohort Study
16%
Severe COVID-19 Infection
16%
S-IgG Antibodies
16%
Medicine and Dentistry
Anti-Inflammatory Drug
100%
Prospective Cohort Study
100%
Severe Acute Respiratory Syndrome
100%
Interstitial Lung Disease
100%
Humoral Immunity
100%
Idiopathic Pulmonary Fibrosis
85%
Arm
57%
Immune Response
28%
Immunosuppressive Treatment
28%
Infection
14%
COVID-19
14%
Rituximab
14%
Immunoglobulin G Antibody
14%
COVID-19 Vaccine
14%
Immunology and Microbiology
Vaccine Efficacy
100%
Humoral Immunity
100%
Severe Acute Respiratory Syndrome
100%
Arm
57%
Antibody Titer
42%
Immunosuppression
28%
Immune Response
28%
COVID-19
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Seropositivity
14%
Spike
14%
Titer
14%
Immunoglobulin G Antibody
14%
Rituximab
14%
Vaccination Policy
14%
Serology
14%
Pharmacology, Toxicology and Pharmaceutical Science
Anti-Inflammatory Drug
100%
Prospective Cohort Study
100%
Severe Acute Respiratory Syndrome
100%
Interstitial Lung Disease
100%
Fibrosing Alveolitis
85%
COVID-19 Vaccine
14%
Infection
14%
Rituximab
14%
Immunoglobulin G Antibody
14%
Vaccination Policy
14%